View Post Clinical Impact and Cost of Laboratory Monitoring Need Review Even in Resource-Rich Setting. Journal of Acquired Immune Deficiency Syndromes, 56(3): e97-e98. In by AHFMarch 1, 2011
View Post A Perspective on the Proposal for Neurocognitive Disorder Criteria in DSM-5 as Applied to HIV-Associated Neurocognitive Disorders. Neuropsychiatry, 1(5): 431-440. In by AHFJanuary 15, 2011
View Post The 104 Day Report: A Successful Intervention of Improving Patient Retention. Clinical Infectious Diseases, 51(7): 868-869. In by AHFOctober 1, 2010
View Post Improving Prevention of Mother-to-Child Transmission of HIV Care and Related Services in Eastern Rwanda. PLOS Medicine, 7(7): 1-5. In by AHFJuly 1, 2010
View Post Screening and Management of Anal Dysplasia and Anal Cancer in HIV-Infected Patients: A Guide for Practice. Journal of the Association of Nurses in AIDS Care, 21(5): 408-416. In by AHFApril 16, 2010
View Post Efficacy, Safety, and Tolerability of Etravirine With and Without Darunavir/Ritonavir or Raltegravir in Treatment-Experienced Patients: Analysis of the Etravirine Early Access Program in the United States. Journal of Acquired Immune Deficiency Syndrome, 53(5): 614-618. In by AHFApril 1, 2010
View Post DART and Laboratory Monitoring of HIV Treatment. The Lancet, 375 (9719): 979. In by AHFMarch 1, 2010
View Post Stop the Sores: The Making and Evaluation of a Successful Social Marketing Campaign. Health Promotion Practice, 11(1): 23-33. In by AHFJanuary 16, 2010
View Post Avoid a Different Standard of Care When Applying Results of Development of Antiretroviral Therapy in Africa (DART) Study. Journal of Acquired Immune Deficiency Syndromes, 53(1): 153-154. In by AHFJanuary 1, 2010
